{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:14:57Z","timestamp":1792440897437,"version":"4.5.0"},"reference-count":18,"publisher":"Pharmaceutical Society of Japan","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2025,8,5]]},"DOI":"10.1248\/bpb.b25-00126","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T22:07:35Z","timestamp":1754345255000},"page":"1185-1190","source":"Crossref","is-referenced-by-count":4,"title":["Subsidy Programs for Herpes Zoster Vaccination in Japanese Municipalities"],"prefix":"10.1248","volume":"48","author":[{"given":"Aiko","family":"Shono","sequence":"first","affiliation":[{"name":"Laboratory of Public Health, Showa Pharmaceutical University, 3\u20132\u20131 Higashi-Tamagawagakuen, Machida, Tokyo 194\u20138543, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-ling","family":"Hoshi","sequence":"additional","affiliation":[{"name":"Department of Health Care Policy and Health Economics, Institute of Medicine, University of Tsukuba, 1\u20131\u20131 Tennoudai, Tsukuba, Ibaraki 305\u20138577, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahide","family":"Kondo","sequence":"additional","affiliation":[{"name":"Department of Health Care Policy and Health Economics, Institute of Medicine, University of Tsukuba, 1\u20131\u20131 Tennoudai, Tsukuba, Ibaraki 305\u20138577, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Cohen JI. Clinical practice: herpes zoster. <i>N. Engl. J. Med.<\/i>, <b>369<\/b>, 255\u2013263 (2013).","DOI":"10.1056\/NEJMcp1302674"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Gilden DH, Kleinschmidt-DeMasters BK, LaGuardia JJ, Mahalingam R, Cohrs RJ. Neurologic complications of the reactivation of varicella-zoster virus. <i>N. Engl. J. Med.<\/i>, <b>342<\/b>, 635\u2013645 (2000).","DOI":"10.1056\/NEJM200003023420906"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Pan CX, Lee MS, Nambudiri VE. Global herpes zoster incidence, burden of disease, and vaccine availability: a narrative review. <i>Ther. Adv. Vaccines Immunother.<\/i>, <b>10<\/b>, 25151355221084535 (2022).","DOI":"10.1177\/25151355221084535"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Johnson RW, Levin MJ. Herpes zoster and its prevention by vaccination. <i>Interdiscip. Top. Gerontol. Geriatr.<\/i>, <b>43<\/b>, 131\u2013145 (2020).","DOI":"10.1159\/000504484"},{"key":"5","unstructured":"5) U.S. Centers for disease control and prevention. \u201cShingles Vaccine Recommendations.\u201d: &lt;https:\/\/www.cdc.gov\/shingles\/hcp\/vaccine-considerations\/&gt;, accessed 23 May, 2025."},{"key":"6","unstructured":"6) Department of Health and Aged Care. \u201cAustralian Government. Zoster (helpes zoster).\u201d: &lt;https:\/\/www.health.gov.au\/topics\/immunisation\/vaccines\/shingles-herpes-zoster-immunisation-service&gt;, accessed 17 September, 2024."},{"key":"7","unstructured":"7) Government of Canada. \u201cHerpes zoster (shingles) vaccine: Canadian Immunization Guide.\u201d: &lt;https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/healthy-living\/canadian-immunization-guide-part-4-active-vaccines\/page-8-herpes-zoster-(shingles)-vaccine.html&gt;, accessed 23 May, 2025."},{"key":"8","unstructured":"8) Government of UK. \u201cShingles (herpes zoster): the green book, chapter 28a.\u201d: &lt;https:\/\/www.gov.uk\/government\/publications\/shingles-herpes-zoster-the-green-book-chapter-28a&gt;, accessed 20 June, 2024."},{"key":"9","unstructured":"9) U.K. Health Security Agency. \u201cShingles immunization programme: information for healthcare practitioners.\u201d &lt;https:\/\/www.gov.uk\/government\/publications\/shingles-vaccination-guidance-for-healthcare-professionals\/shingles-immunisation-programme-information-for-healthcare-practitioners&gt;, accessed 23 May, 2025."},{"key":"10","unstructured":"10) Varicella vaccine live attenuated \u201cBIKEN\u201d. &lt;https:\/\/www.biken.or.jp\/upload\/product\/document_pdf\/fa-v\/document_mt.pdf&gt;, accessed 20 June, 2024."},{"key":"11","unstructured":"11) Watanabe D. Vaccine ni yoru Taijohoushin yobou. <i>Gendai Igaku<\/i>, <b>68<\/b>, 37\u201341 (2021)."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Asada H. Recent topics in the management of herpes zoster. <i>J. Dermatol.<\/i>, <b>50<\/b>, 305\u2013310 (2023).","DOI":"10.1111\/1346-8138.16666"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Fundytus K, Santamaria-Plaza C, McLaren L. Policy diffusion theory, evidence-informed public health, and public health political science: a scoping review. <i>Can. J. Public Health<\/i>, <b>114<\/b>, 331\u2013345 (2023).","DOI":"10.17269\/s41997-023-00752-x"},{"key":"14","unstructured":"14) Zenkoku Hoken-I Dantai Rengoukai. \u201cTaijohoushin vaccine josei jigyou jichitai ichiran.\u201d: &lt;https:\/\/hodanren.doc-net.or.jp\/info\/investigation\/202506subsidy\/&gt;, accessed 5 July, 2024."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Strezova A, Diez-Domingo J, Al Shawafi K, Tinoco JC, Shi M, Pirrotta P, Mwakingwe-Omari A. Long-term protection against herpes zoster by the adjuvanted recombinant zoster vaccine: interim efficacy, immunogenicity, and safety results up to 10 years after initial vaccination. <i>Open Forum Infect. Dis.<\/i>, <b>9<\/b>, ofac485 (2022).","DOI":"10.1093\/ofid\/ofac492.192"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Naito T, Suzuki M, Fujibayashi K, Kanazawa A, Takahashi H, Yokokawa H, Watanabe A. The estimated impact of the 5-year national vaccination program on the trend of 23-valent pneumococcal polysaccharide vaccine vaccination rates in the elderly in Japan, 2009\u20132018. <i>J. Infect. Chemother.<\/i>, <b>26<\/b> (2020) 407\u2013410.","DOI":"10.1016\/j.jiac.2019.12.011"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Shono A, Hoshi SL, Kondo M. The impact on vaccination coverage following introduction of a routine pneumococcal vaccination programme for the elderly in Japan. <i>Vaccine<\/i>, <b>36<\/b>, 5886\u20135890 (2018).","DOI":"10.1016\/j.vaccine.2018.08.023"},{"key":"18","unstructured":"18) Ministry of Health, Labour and Welfare. \u201cZoster vaccine.\u201d: &lt;https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/kenkou_iryou\/kenkou\/kekkaku-kansenshou\/yobou-sesshu\/vaccine\/shingles\/index.html.&gt;, accessed 17 May, 2025."}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/8\/48_b25-00126\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T03:52:35Z","timestamp":1754711555000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/8\/48_b25-00126\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,5]]},"references-count":18,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b25-00126","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,5]]},"article-number":"b25-00126"}}